New RAPID Coverage Pathway Streamlines Device Approval Process

The Centers for Medicare & Medicaid Services (CMS) and the Food and Drug Administration (FDA) have introduced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway to accelerate the coverage process for specific medical devices. This initiative focuses on FDA-designated Class II and Class III Breakthrough Devices to enhance Medicare access. By streamlining regulatory processes, RAPID aims to address AI-driven prior authorization delays and improve overall operational efficiency.

RAPID fosters collaboration between CMS and FDA by engaging medical device manufacturers early in the product development cycle. This proactive approach allows evidence collected during the FDA's evaluations to also influence Medicare coverage decisions. As a result, the delays often seen between FDA approval and coverage determination are reduced, aligning regulatory compliance requirements with expedited market entry.

A procedural notice detailing the RAPID pathway is expected in the Federal Register, initiating a 60-day public comment period. Following this, CMS will issue a final notice to officially launch the pathway. Dr. Mehmet Oz, CMS administrator, emphasized the importance of early coordination in approving medical devices to streamline regulatory compliance and enhance patient access to innovative technologies.

Amid broader infrastructural changes within the U.S. Department of Health and Human Services (HHS), efforts to increase efficiency are highlighted by the FDA's AI-based tool Elsa and CMS's application of AI for pre-approval processes like prior authorization. While these technologies advance regulatory procedures, maintaining human oversight ensures safe implementation. CMS is also piloting the Tempo program to improve access to digital health devices through a risk-based enforcement strategy, reflecting a commitment to cost efficiency and compliance simplification across health agencies.